Cargando…

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases

BACKGROUND: In-transit metastases (ITMs) affect approximately 4% of patients with cutaneous melanoma. This study sought to identify clinical and pathological characteristics that predict further recurrence and survival following resection of ITMs. PATIENTS AND METHODS: Patients (n = 573) who underwe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawless, Anna K., Coker, David J., Lo, Serigne N., Ahmed, Tasnia, Scolyer, Richard A., Ch’ng, Sydney, Nieweg, Omgo E., Shannon, Kerwin, Spillane, Andrew, Stretch, Jonathan R., Thompson, John F., Saw, Robyn P. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492704/
https://www.ncbi.nlm.nih.gov/pubmed/35771368
http://dx.doi.org/10.1245/s10434-022-11997-0
_version_ 1784793536258899968
author Lawless, Anna K.
Coker, David J.
Lo, Serigne N.
Ahmed, Tasnia
Scolyer, Richard A.
Ch’ng, Sydney
Nieweg, Omgo E.
Shannon, Kerwin
Spillane, Andrew
Stretch, Jonathan R.
Thompson, John F.
Saw, Robyn P. M.
author_facet Lawless, Anna K.
Coker, David J.
Lo, Serigne N.
Ahmed, Tasnia
Scolyer, Richard A.
Ch’ng, Sydney
Nieweg, Omgo E.
Shannon, Kerwin
Spillane, Andrew
Stretch, Jonathan R.
Thompson, John F.
Saw, Robyn P. M.
author_sort Lawless, Anna K.
collection PubMed
description BACKGROUND: In-transit metastases (ITMs) affect approximately 4% of patients with cutaneous melanoma. This study sought to identify clinical and pathological characteristics that predict further recurrence and survival following resection of ITMs. PATIENTS AND METHODS: Patients (n = 573) who underwent surgical resection of their first presentation of ITM following previous surgical treatment of an American Joint Committee on Cancer (AJCC) stage I–II melanoma between 1969 and 2017 were identified from an institutional database. Clinicopathological predictors of patterns of recurrence and survival following ITM resection were sought. RESULTS: The median time of ITM development was 2.4 years after primary melanoma resection. ITMs were most frequently located on the lower limb (51.0%). The most common melanoma subtype associated with ITM development was nodular melanoma (44.1%). After surgical resection of a first ITM, 65.4% of patients experienced recurrent disease. Most recurrences were locoregional (44.7%), with distant metastasis occurring in 23.9% of patients. Lower limb ITMs were more frequently associated with subsequent ITMs [odds ratio (OR) 2.41, p = 0.0002], and the lowest risk of distant metastasis (p < 0.0001) compared with other primary sites. Primary melanomas and ITM on head and neck, as well as the presence of ulceration, were associated with worse survival. CONCLUSIONS: Recurrence after surgical resection of a first ITM was common. Patterns of recurrence differed according to anatomical site; further ITM recurrences were more likely for lower limb ITMs, which were also associated with longer distant recurrence-free survival. Distant metastasis was more common for ITM on the head and neck, with worse survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11997-0.
format Online
Article
Text
id pubmed-9492704
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-94927042022-09-23 Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases Lawless, Anna K. Coker, David J. Lo, Serigne N. Ahmed, Tasnia Scolyer, Richard A. Ch’ng, Sydney Nieweg, Omgo E. Shannon, Kerwin Spillane, Andrew Stretch, Jonathan R. Thompson, John F. Saw, Robyn P. M. Ann Surg Oncol Melanoma BACKGROUND: In-transit metastases (ITMs) affect approximately 4% of patients with cutaneous melanoma. This study sought to identify clinical and pathological characteristics that predict further recurrence and survival following resection of ITMs. PATIENTS AND METHODS: Patients (n = 573) who underwent surgical resection of their first presentation of ITM following previous surgical treatment of an American Joint Committee on Cancer (AJCC) stage I–II melanoma between 1969 and 2017 were identified from an institutional database. Clinicopathological predictors of patterns of recurrence and survival following ITM resection were sought. RESULTS: The median time of ITM development was 2.4 years after primary melanoma resection. ITMs were most frequently located on the lower limb (51.0%). The most common melanoma subtype associated with ITM development was nodular melanoma (44.1%). After surgical resection of a first ITM, 65.4% of patients experienced recurrent disease. Most recurrences were locoregional (44.7%), with distant metastasis occurring in 23.9% of patients. Lower limb ITMs were more frequently associated with subsequent ITMs [odds ratio (OR) 2.41, p = 0.0002], and the lowest risk of distant metastasis (p < 0.0001) compared with other primary sites. Primary melanomas and ITM on head and neck, as well as the presence of ulceration, were associated with worse survival. CONCLUSIONS: Recurrence after surgical resection of a first ITM was common. Patterns of recurrence differed according to anatomical site; further ITM recurrences were more likely for lower limb ITMs, which were also associated with longer distant recurrence-free survival. Distant metastasis was more common for ITM on the head and neck, with worse survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11997-0. Springer International Publishing 2022-06-30 2022 /pmc/articles/PMC9492704/ /pubmed/35771368 http://dx.doi.org/10.1245/s10434-022-11997-0 Text en © Crown 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Melanoma
Lawless, Anna K.
Coker, David J.
Lo, Serigne N.
Ahmed, Tasnia
Scolyer, Richard A.
Ch’ng, Sydney
Nieweg, Omgo E.
Shannon, Kerwin
Spillane, Andrew
Stretch, Jonathan R.
Thompson, John F.
Saw, Robyn P. M.
Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
title Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
title_full Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
title_fullStr Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
title_full_unstemmed Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
title_short Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
title_sort clinicopathological characteristics predicting further recurrence and survival following resection of in-transit melanoma metastases
topic Melanoma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492704/
https://www.ncbi.nlm.nih.gov/pubmed/35771368
http://dx.doi.org/10.1245/s10434-022-11997-0
work_keys_str_mv AT lawlessannak clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT cokerdavidj clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT loserignen clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT ahmedtasnia clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT scolyerricharda clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT chngsydney clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT niewegomgoe clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT shannonkerwin clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT spillaneandrew clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT stretchjonathanr clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT thompsonjohnf clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases
AT sawrobynpm clinicopathologicalcharacteristicspredictingfurtherrecurrenceandsurvivalfollowingresectionofintransitmelanomametastases